May 24, 2019 Time to restock big pharma’s leaking pipeline The number of late-stage assets in the hands of the industry’s behemoths is shrinking, and this can only put more pressure on companies to do deals.
May 21, 2019 Merck sees potential in Peloton Peloton Therapeutics’ approach to fighting kidney tumours has apparently convinced Merck & Co, which is to pay $1.05bn for the company on the back of relatively little clinical data.
April 10, 2019 Venture funding slowdown continues in first quarter of 2019 Venture funding drops again, but there’s no need to panic yet.
